On Tuesday, Shattuck Labs, Inc. STTK inventory traded decrease, with a session quantity of 9.48 million versus the common quantity of 328.32k. The corporate introduced a strategic pipeline prioritization.
Shattuck will discontinue its medical program, SL-172154, and give attention to SL-325, its DR3 antagonist antibody. Shattuck Labs plans to provoke medical growth in sufferers with inflammatory bowel illness.
Roughly 40% of Shattuck’s workforce might be impacted by the adjustments. The corporate expects to finish the discount in drive within the fourth quarter of 2024.
The corporate says its money and money equivalents and investments might be enough to fund its deliberate operations into 2027.
Shattuck expects to file an investigational new drug for SL-325 within the third quarter of 2025. Topline Part 1B SL-172154 trial in higher-risk myelodysplastic syndromes (HR-MDS) confirmed median total survival of 15.6 months. The median survival for sufferers with TP53m HR-MDS is 10.6 months and won’t enhance past 13.1 months with subsequent information cuts.
Benchmark median total survival of roughly 9–12 months for TP53m HR-MDS sufferers handled with Bristol Myers Squibb & Co’s BMS Vidaza (azacitidine) alone.
In TP53m acute myeloid leukemia (AML) sufferers, median total survival was 10.5 months and won’t enhance past 11.7 months with subsequent information cuts.
Benchmark median OS of roughly 5-8 months for TP53m AML sufferers handled with azacitidine alone.
The corporate mentioned approval of SL-172154 in TP53m AML and HR-MDS would require significant enchancment in OS in large-scale, randomized research. The corporate noticed solely modest enhancements in OS in its Part 1 trial, and traditionally, some erosion in efficacy can be anticipated in bigger, randomized trials.
“We’re disenchanted that the promising full remission charges we beforehand shared from our Part 1 medical trial didn’t translate to clinically significant enhancements in median total survival for TP53m AML and HR-MDS sufferers handled with SL-172154 together with azacitidine,” mentioned Taylor Schreiber, CEO of Shattuck.
Shattuck and Ono Pharmaceutical Co., Ltd. agreed to terminate the license settlement associated to the preclinical growth of sure compounds.
Worth Motion: STTK inventory is down 42.4% to $2.01 on the final examine Tuesday.
Learn Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
